Changes in sexual risk behavior among participants in a PrEP HIV prevention trial

Sex Transm Dis. 2008 Dec;35(12):1002-8.

Abstract

Background: One of the concerns raised regarding the introduction of any new HIV-prevention measure, such as PrEP, is the potential for risk disinhibition or sexual risk compensation. The oral tenofovir HIV prevention trial has been the subject of international discussion in this regard.

Methods: This article maps the changes in sexual risk behavior among women participating in the oral tenofovir HIV prevention trial in Ghana. Content-driven, thematic analysis was carried out on qualitative data obtained from in-depth interviews with study participants. Growth curve analysis was the primary method used to document trends over time in self-reported sexual behavior collected monthly.

Results: Overall, the study found that sexual risk behavior did not increase during the trial. Number of sexual partners and rate of unprotected sex acts decreased across the 12-month period of study enrollment. Certain subgroups of women, however, exhibited different growth curves. Data indicate that the HIV prevention counseling associated with the trial was effective.

Conclusions: Counseling during the trial was effective. Different types of counseling and messaging may be needed for different subgroups within a population. These findings also have implications for required sample sizes for future HIV prevention trials where seroconversion is the main outcome.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adolescent
  • Adult
  • Anti-HIV Agents* / administration & dosage
  • Anti-HIV Agents* / therapeutic use
  • Counseling
  • Double-Blind Method
  • Female
  • Ghana
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • Humans
  • Interviews as Topic
  • Male
  • Organophosphonates* / administration & dosage
  • Organophosphonates* / therapeutic use
  • Reverse Transcriptase Inhibitors* / administration & dosage
  • Reverse Transcriptase Inhibitors* / therapeutic use
  • Risk Reduction Behavior*
  • Risk-Taking
  • Sexual Behavior / statistics & numerical data*
  • Sexual Partners
  • Surveys and Questionnaires
  • Tenofovir
  • Treatment Outcome
  • Unsafe Sex
  • Young Adult

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Adenine